MAIA Biotechnology to Participate in the 36th Annual ROTH Conference

On March 7, 2024 MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, reported its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 in Dana Point, California (Press release, MAIA Biotechnology, MAR 7, 2024, View Source [SID1234640948]). Chief Executive Offer Vlad Vitoc, M.D. will host one-on-one meetings with institutional investors and analysts on Monday, March 18th and Tuesday, March 19th.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Location:

The Ritz Carlton, Laguna Niguel in Dana Point, California.

Registration:

Available on the conference website.

1×1 meetings:

Investors may request a meeting by contacting a ROTH
representative at 800.678.9147 or by contacting MAIA investor Relations.

MAIA’s lead candidate is THIO, a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses. THIO’s efficacy in non-small cell lung cancer (NSCLC) is being evaluated in THIO-101, a Phase 2 go-to-market clinical trial nearing completion, which is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment. MAIA plans to pursue the FDA’s accelerated approval program for THIO.

Recent news from MAIA’s THIO-101 trial includes:

Early completion of enrollment; trial nears completion with topline data expected in second half of 2024; (press release, February 22, 2024)
Strong response rate of 38% in third-line treatment efficacy data; (press release, March 6, 2024).
Multiple paths to potential commercial approval of THIO under consideration; MAIA anticipates a final FDA decision on THIO in 2026; (MAIA Shareholder Letter 2024).